Pfizer PFE Biopharma — Selling, informational and administrative expenses

Similar metrics at other companies

BDXBioPharma Systems — Selling and administrative expense

$32M+14.3%

BAXPharmaceuticals — Selling, general and administrative expenses

$102M-1.0%

TMOLaboratory Products and Biopharma Services — Selling, general and administrative expenses

$597M+1.5%

BDXBioPharma Systems — Segment Selling and Administrative as a Percent of Revenues

5.4%+0.6pp

VRTXPharmaceuticals — Selling and other commercial expenses

$313.6M+30.1%

LHBiopharma Laboratory Services — Other Cost and Expense, Operating

$89.7M-0.3%

Questions, answered.

What is Pfizer's biopharma — selling, informational and administrative expenses?

Pfizer (PFE) reported biopharma — selling, informational and administrative expenses of $2.13B in Q1 2026.

How has Pfizer's biopharma — selling, informational and administrative expenses changed year-over-year?

Pfizer's biopharma — selling, informational and administrative expenses decreased by 2.5% year-over-year, from $2.19B to $2.13B.

What is the long-term trend for Pfizer's biopharma — selling, informational and administrative expenses?

Over 3 years (2022 to 2025), Pfizer's biopharma — selling, informational and administrative expenses has grown at a 1.4% compound annual growth rate (CAGR), from $9.21B to $9.6B.

What does biopharma — selling, informational and administrative expenses mean?

Operating expenses related to marketing, sales force support, medical information dissemination, and general administrative overhead for the biopharma segment. These costs support the commercialization and maintenance of the product portfolio.